Peppermint Oil Dyspepsia Randomized Trial: What the Evidence Says

Quick Answer

Peppermint Oil Dyspepsia Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are guideline, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 guideline, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The S1 guideline summarizes the current state of knowledge and allows a targeted approach based on the currently available medical evidence. [Storr M (2026); evidence level 2]
• Functional dyspepsia (FD) is common and classified as a disorder of gut-brain interaction (DGBI). [Storr M (2026); evidence level 2]
• Results During treatment, all assessed abdominal symptoms showed significant (p Conclusion The study demonstrates patient-relevant improvement in gastrointestinal symptoms during treatment with Menthacarin while underlining its favorable tolerability profile. [Linas I (2025); evidence level 2]
• Introduction In disorders of gut-brain interaction including functional dyspepsia and irritable bowel syndrome, clinical focus has shifted from pathophysiological criteria to symptoms. [Linas I (2025); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For peppermint oil dyspepsia randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Storr M (2026). S1 Guideline of the German Society for Neurogastroenterology and Motility (DGNM) on Functional Dyspepsia (FD), a Disorder of Gut-Brain Interaction (DGBI) [English Language Edition].. DOI: 10.1155/grp/2610765. PMCID: PMC13140302. PMID: 42095009. https://pmc.ncbi.nlm.nih.gov/articles/PMC13140302/
• Linas I (2025). Treatment of disorders of gut-brain interaction with peppermint oil and caraway oil combination Menthacarin : A phase IV clinical trial.. DOI: 10.1007/s10354-025-01119-2. PMCID: PMC13013221. PMID: 41405807. https://pmc.ncbi.nlm.nih.gov/articles/PMC13013221/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.